MaxCyte Inc (MXCT) FinancialsMXCTMaxCyte Inc

MaxCyte Inc (MXCT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product, accounting for 56.4% of total sales, equivalent to $4.10M. Other significant revenue streams include Product sales and Licenses. Understanding this composition is critical for investors evaluating how MXCT navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, MaxCyte Inc maintains a gross margin of 63.86%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -140.72%, while the net margin is -122.05%. These profitability ratios, combined with a Return on Equity (ROE) of -20.39%, provide a clear picture of how effectively MXCT converts its operational activities into shareholder value.

In the context of the broader market, MXCT competes directly with industry leaders such as PEPG and VRXA. With a market capitalization of $134.17M, it holds a significant position in the sector. When comparing efficiency, MXCT's gross margin of 63.86% stands against PEPG's N/A and VRXA's N/A. Such benchmarking helps identify whether MaxCyte Inc is trading at a premium or discount relative to its financial performance.

MaxCyte's gross margin is 63.86%, indicating good profitability on sales, but it has reported consistent net losses, including $8.87 million in Q2 2026. The company has a current ratio of 12.26, suggesting strong liquidity.